Changes in Hong Kong stocks | Collumbotai Biotech (06990) rose by more than 11%, and the Phase 3 study of the core product Lianzhi PD-L1 Negative NSCLC reached the main end

The Zhitong Finance App learned that Columbotai Biotech (06990) rose by more than 11%. As of press release, it had risen 11% to HK$553, with a turnover of HK$356 million.

According to the news, Columbotai Biotech announced this morning that its core products are locally-advanced or metastatic non-squamous non-squamous non-small cell lung cancer (ADC) targeting human trophic cell surface antigen 2 (TROP2), plus MSD's anti-programmed cell death protein-1 (PD-1) monoclonal antibody (monoclonal antibody), pavolizumab (Coreda®), first-line treatment programs negative for cell death ligand-1 (PD-L1) CLC) Phase 3 clinical study, in a predetermined mid-term analysis, Reach the primary end of progression-free survival (PFS).

This is the world's first phase 3 clinical study of ADC combined with an immune checkpoint inhibitor to reach the primary endpoint in first-line treatment of negative PD-L1 negative non-squamous NSCLC. The company plans to communicate with the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) about the results of the lucan satuzumab (Sac-TMT) study.